HepatoChem at the New Jersey DMDG

NJACS-atom-logo-44x2191HepatoChem will be attending the New Jersey Drug Metabolism Discussion Group Spring Symposium on May 1, 2014 at The Palace at Somerset Park in Somerset, NJ. Be sure to visit us to hear about our latest technologies!

HepatoChem, Inc. Designs Innovative Tools for the Life Sciences Industry

HepatoChem has developed extensive capabilities to quickly survey organo-metallic chemistry systems and design innovative tools for the pharmaceutical industry. It has most recently commercialized the BMO (BioMimetic Oxidation) Kit, which utilizes rapid one step biomimetic chemistry to generate useful quantities of drug candidate metabolites.  Applying a similar developmental approach, HepatoChem is now providing unique tools for the instant and flexible diversification of biologically active small molecules. These tools are largely centered on fluorination chemistry. HepatoChem is currently working with Vertex, a local biotech based in Boston, MA, to develop tools to allow for fast discovery of fluorinated analogues of small molecules, which Vertex scientists will employ in their own projects.

HepatoChem Co-founder and President Marc Bazin stated “Our work with Vertex is an extraordinary opportunity to demonstrate the versatility of HepatoChem’s platform. We are all committed to the development of innovative tools, such as chemical diversification kits, for companies that are seeking to discover and develop new medicines. “

About HepatoChem, Inc.

Founded in 2008, HepatoChem is an early-stage company that offers innovative services and products to the pharmaceutical industry. Our core expertise is organo-metallic catalysis and high-throughput compound analysis. HepatoChem received the Accelerator Loan from Mass Life Sciences Center in 2012 and is located in Beverly, MA at NorthShore InnoVentures (NSIV).


HepatoChem, Inc.

100 Cummings Center, Suite 424J

Beverly, MA 01915

Phone: (617) 500-5285

Fax: (617) 274-0827

HepatoChem mentioned in recent BMCL Digest article

HepatoChem is mentioned in a recent Bioorganic & Medicinal Chemistry Letters Digest article entitled, ‘Emerging technologies for metabolite generation and structural diversification‘. Be sure to check out the article at www.sciencedirect.com !

Cusack, Kevin P.; Vasudevan, Anil. Emerging technologies for metabolite generation and structural diversification. Bioorganic & Medicinal Chemistry Letters 23, 2013, 5471–5483.

HepatoChem at the Boston-PBSS

HepatoChem will be attending Boston Pharmaceutical & BioScience Society Workshop in Cambridge on Friday October 25th. Be sure to stop by and visit our booth!

HepatoChem at the International ISSX Meeting in Toronto

ISSX Toronto Meeting

HepatoChem will be attending The 10th International ISSX Meeting in Toronto from September 29th to October 2nd to unveil our new BMO Kit. Be sure to stop by and visit us at booth 505!

North Shore InnoVentures provides more than just lab and office space

In Salem News

BEVERLY — Early stage life sciences and “cleantech” companies that are part of the nonprofit business incubator North Shore InnoVentures are benefiting not only from reduced rates for lab and office space, but from the advice and networking it offers.

“To be successful, you can’t do it yourself,” said AdvaStim co-founder and Chief Technology Officer Barry Yomtov, whose medical device startup was one of the first to join North Shore InnoVentures.

“Networking is the biggest part,” said Martha Farmer, president and CEO of North Shore InnoVentures.

see more http://www.salemnews.com/business/x1525001303/Helping-startups-find-success



Reactive Metabolites Symposium

The 2nd Mitigation Strategies for Reactive Metabolites is the only meeting dedicated to helping you implement more effective risk assessment strategies for reactive metabolites in your organization and truly minimize the attrition of your pipeline.

November 27-29, 2012 at Revere Hotel, Boston, MA


ISSX North American Meeting

HepatoChem will be present at the ISSX North American meeting on October 14th-18th in Dallas, Texas, USA.

Please come to visit us at the booth 113

HepatoChem Referenced in Salem News

HepatoChem and NSIV Meets the Governor of MA May 30th at Cummings Park in Beverly. The Salem News references HepatoChem and NSIV in an article referencing the visit of Governor Deval Patrick of Massachusetts on May 30th to Cummings Park complex in Beverly where he honor both their commitment to green energy and life science industries. Click here to read the full article.

HepatoChem Spring 2012 Newsletter

Collaboration With Prof. Michael Pollastri on Lead Diversification

HepatoChem Inc. and Prof. Michael Pollastri at Northeastern University initiated a collaboration on lead diversification of bioactive small molecules. The objective of this partnership is to discover new therapeutics using both the HepatoChem biomimetic technology and Pollastri’s approach, which consists of repurposing optimized human compound classes for neglected tropical diseases.

An example of Prof Pollastri’s approach is a parasitic target like trypanosomal phosphodiesterases has ~30% homology to human PDE4 and 5. That considered it becomes advantageous to use known human PDE4/5 inhibitors as a starting point to develop a new parasitic drug.

HepatoChem will bring its expertise in biomimetic technology to allow fast synthesis of new metabolite-like analogues. Indeed, the diversity expansion inherent in transformations that mimic the metabolism of small molecules and natural products provides a new direction into new chemical space. This new application is the result of the expansion of the spectrum of chemical reactions offered by HepatoChem to include halogenation and amination, in addition to oxidation.

This collaboration is part of the HepatoChem effort to develop and offer innovative tools for drug discovery. For more information about Prof Pollastri http://www.northeastern.edu/pollastri/

HepatoChem is a Recipient of the ‘Mass Life Science Center Life Science Center’s Accelerator Program

Mass Life Science Center Life Sciences Accelerator Program – Announces the 5 FY2012 Recipients on April 24, 2012

We are delighted to learn on April 24th that HepatoChem was one of five early stage companies to be awarded the Massachusetts Life Science Center Accelerator Program Loan for FY2012. “The $330,000.00 loan has arrived at the right time. Each month, small to big pharmaceutical organizations are turning to us to help them produce and characterize their drug candidate metabolites faster and in larger quantities than they could trying more traditional methods. To learn more …

Cationic Iron(III) Porphyrin-Catalyzed [4 + 2] Cycloaddition of Unactivated Aldehydes with Simple Dienes

Usually iron porphyrin complexes are studies as models of heme proteins and as biomimetic oxidation catalysts. Interestingly, simple iron porphyrins can also catalyze other important transformations of organic compounds. The team of Kyohei Fujiwara, Takuya Kurahashi, and Seijiro Matsubara at Kyoto University have reported that the readily available cationic tetraphenyl iron(III) porphyrin (FeTPP) is an efficient catalyst for the highly chemoselective hetero-Diels−Alder reaction of aldehydes with conjugated dienes.

This reaction is one of the most powerful synthetic methods for the construction of heterocyclic compounds containing the pyran structural motif and has been widely applied in the preparation of drugs and natural products. Significantly, the process did not require activated reaction partners. A crystal structure of the catalyst shows that aryl aldehydes are activated by the catalyst via coordination of the carbonyl oxygen to the iron(III) center. High functional group tolerance was observed and a large variety of cycloadduct products were obtained in good to excellent yield. For example, phenyl-acetaldehyde underwent cycloaddition to afford a pyran in 72% yield. Thus, the catalyst is apparently able to suppress the high tendancy of this substrate to enolize. Cyclopropane carboxaldehyde, which is sensitive to rearrangement, also fomed a pyran in good yield. Significantly, the catalyst was shown to tolerate the presence of water.

Kyohei Fujiwara, Takuya Kurahashi, and Seijiro Matsubara, J. Am. Chem. Soc. 2012, 134, 5512−5515

Proximal Ligand Electron Donation and Reactivity of the Cytochrome P450 Ferric−Peroxo Anion

Cytochrome P450 enzymes, also called CYPs, are heme proteins with unusual cycteine-derived axial thiolate ligands that catalyze a wide variety of biological oxidations. In humans so-caled phase I metabolism of drugs results from P450-mediated oxidations. However, thousands of P450 proteins have been identified throughout biology that oxygenate all sorts of organic compounds compounds, including fatty acids, steroids, and xenobiotics. For a vast majority of bacterial P450s the subsrates and functions remain unknown. Some, such as EryF, are known to be involved in the biosynthesis of antibiotics, while others, such as P450cam (CYP101) are involved terpene catabolism.

CYP125 from Mycobacterium tuberculosis catalyzes the conversion of the terminal side-chain methyl group of cholesterol to various oxygenated states, alcohol, aldehyde and carboxylic acid. Paul R. Ortiz de Montellano and his group at UC San Francisco have recently reported that that CYP125 also the deformylation of the sterol side chain. The aldehyde intermediate is shown to be the precursor of both the conventional acid metabolite and the five deformylation products. These deformylation products are thought to arise from a reaction of the aldehyde intermedaite with a deprotonated ferric-peroxo intermediate, (heme)Fe(III)-O-O-. Replacement of the coordinating cysteine sulfur with selenium led to a product distribution with less of the deformylation products and more terminal side chain carboxylic acid. The results are interpreted to derive from an increase in the pKa of the ferric− peroxo anion in the selenium derivative as compared to the natural cysteine sulfur coordination.

In the early stages of MTb infection, the bacterium invades the aveolar macrophage (white) cells of the lung. These are the very cells usually responsible for bacterial killing and general house keeping. Remarkably, however, MTb is able to disable the bacteriocidal activities of the aveolar macrophage and propagate within the host cell. Once ensconced within the host, MTb uses cholesterol derived from the host as food. Furthermore, the steroid nucleus is then tailored by various oxidizing proteins in the bacterium to extend its control over the host cell. Studies such as these that reveal the pathways used by MTb to manipulate cholesterol may reveal drugable targets to help control this terrible disease.

Santhosh Sivaramakrishnan, Hugues Ouellet, Hirotoshi Matsumura,Shenheng Guan, Pierre Moënne-Loccoz, Alma L. Burlingame,and Paul R. Ortiz de Montellano, J. Am. Chem. Soc. 2012, ASAP, published on-line March 23, 2012. DOI: 10.1021/ja211499q

HepatoChem Presents at Early Stage Technology Event

UMASS MATTC Center’s VII Annual Event Features HepatoChem
Marc Bazin, CEO President, and Co-Founder, HepatoChem presented at the UMASS MATTC Center’s VII Annual ‘The Early-Stage Life Sciences Technology Conference’ on Thursday, April 12, 2012 at the Merck Research Laboratories to over 200 angel investors, venture capitalists and corporate investors. For more information…..

Nucleus Article About HepatoChem Reachs the Greater Boston ACS Community

In a recent article of the Nucleus, the newspaper of the New-England ACS section, HepatoChem’s president was interviewed. You can find this article on the NE-ACS website. For more details – http://www.nesacs.org/
For more information contact:

Shelley Amster, Director Business Development, HepatoChem
Phone: (978) 371-5901
Mobile: (978) 239-1468
Email: shelley.amster@hepatochem.com